AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q3 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics. This complimentary, digital source of industry information supports the specialty drug market needs of all stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that may impact millions of individuals living with or affected by rare disease or complex, chronic conditions.

To read more, click here.